These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 19962288

  • 21. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK.
    Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
    [Abstract] [Full Text] [Related]

  • 22. Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder.
    Uehleke B, Schaper S, Dienel A, Schlaefke S, Stange R.
    Phytomedicine; 2012 Jun 15; 19(8-9):665-71. PubMed ID: 22475718
    [Abstract] [Full Text] [Related]

  • 23. No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
    Heger-Mahn D, Pabst G, Dienel A, Schläfke S, Klipping C.
    Drugs R D; 2014 Dec 15; 14(4):265-72. PubMed ID: 25319228
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam.
    Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Valencia CE, Tortoriello J.
    Planta Med; 2007 Jul 15; 73(8):713-7. PubMed ID: 17562493
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
    Fresquet A, Sust M, Lloret A, Murphy MF, Carter FJ, Campbell GM, Marion-Landais G.
    Ann Pharmacother; 2000 Feb 15; 34(2):147-53. PubMed ID: 10676820
    [Abstract] [Full Text] [Related]

  • 26. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.
    Baldinger P, Höflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2014 Oct 31; 18(4):. PubMed ID: 25522403
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
    Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O.
    Hum Psychopharmacol; 2006 Apr 31; 21(3):139-49. PubMed ID: 16625522
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial.
    Herrera-Arellano A, Jiménez-Ferrer JE, Zamilpa A, García-Alonso G, Herrera-Alvarez S, Tortoriello J.
    Planta Med; 2012 Sep 31; 78(14):1529-35. PubMed ID: 22828921
    [Abstract] [Full Text] [Related]

  • 29. Silexan, an essential oil from flowers of Lavandula angustifolia, is not recognized as benzodiazepine-like in rats trained to discriminate a diazepam cue.
    Silenieks LB, Koch E, Higgins GA.
    Phytomedicine; 2013 Jan 15; 20(2):172-7. PubMed ID: 23207249
    [Abstract] [Full Text] [Related]

  • 30. Lavender Oil Preparation (Silexan) for Treating Anxiety: An Updated Meta-Analysis.
    Generoso MB, Soares A, Taiar IT, Cordeiro Q, Shiozawa P.
    J Clin Psychopharmacol; 2017 Feb 15; 37(1):115-117. PubMed ID: 27861196
    [No Abstract] [Full Text] [Related]

  • 31. Effects of lavender on anxiety: A systematic review and meta-analysis.
    Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F.
    Phytomedicine; 2019 Dec 15; 65():153099. PubMed ID: 31655395
    [Abstract] [Full Text] [Related]

  • 32. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis.
    von Känel R, Kasper S, Bondolfi G, Holsboer-Trachsler E, Hättenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E.
    Brain Behav; 2021 Apr 15; 11(4):e01997. PubMed ID: 33638614
    [Abstract] [Full Text] [Related]

  • 33. Effect of anxiolytic drug silexan on sleep - a narrative review.
    Seifritz E, Kasper S, Möller HJ, Volz HP, Müller WE, Eckert A, Hatzinger M.
    World J Biol Psychiatry; 2022 Sep 15; 23(7):493-500. PubMed ID: 36259937
    [Abstract] [Full Text] [Related]

  • 34. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec 15; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 35. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
    Laakmann G, Schüle C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S.
    Psychopharmacology (Berl); 1998 Apr 15; 136(4):357-66. PubMed ID: 9600581
    [Abstract] [Full Text] [Related]

  • 36. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
    Lydiard RB, Rickels K, Herman B, Feltner DE.
    Int J Neuropsychopharmacol; 2010 Mar 15; 13(2):229-41. PubMed ID: 19737439
    [Abstract] [Full Text] [Related]

  • 37. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 15; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 38. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder.
    Cohn JB, Wilcox CS.
    Pharmacotherapy; 1984 Nov 15; 4(2):93-8. PubMed ID: 6144090
    [Abstract] [Full Text] [Related]

  • 39. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC.
    Arch Gen Psychiatry; 2005 Sep 15; 62(9):1022-30. PubMed ID: 16143734
    [Abstract] [Full Text] [Related]

  • 40. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
    Busto UE, Naranjo CA, Bremner KE, Peachey JE, Bologa M.
    J Psychiatry Neurosci; 1998 Jan 15; 23(1):35-44. PubMed ID: 9505058
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.